Most material SEC filings — August 21, 2026

Arbutus Biopharma (market cap ~$472M) announced a modified Dutch auction tender offer to repurchase up to US$230 million of common shares at US$5.00–US$5.75 per share. The offer, expected to commence August 24, 2026 and expire September 29, 2026, will be funded from cash on hand. The company attributed the repurchase to proceeds from its March 2026 settlement with Moderna and July 2026 initial payment, related to licensing its lipid nanoparticle technology.

On August 19, 2026, NYSE American notified Azitra that it has resolved continued listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company will be removed from NYSE American's noncompliant issuers list and the compliance indicator (.BC) will no longer be disseminated. No specific dollar amounts or operational changes were disclosed; this is purely a regulatory/compliance restoration.

Chief Executive Officer Huang Jack Jiajia (COE) bought 325K shares (~$3.9M) on the open market (28% of holdings). Open-market insider purchase — historically a bullish signal.